Overview
Dihydromyricetin (DHM) is a flavonoid compound naturally found in the Hovenia dulcis tree and is gaining attention for its potential to support liver health, alcohol metabolism, and overall recovery.
While the preclinical data is extensive, human research is still limited but encouraging. Below, is a summary of what’s known so far and highlight key considerations for responsible use and future study.
1. Fatty Liver (NAFLD) Randomized Controlled Trial – DHM Alone:
- Design: ~12-week double-blind RCT in adults with non-alcoholic fatty liver disease.
- Dose: ~600 mg/day of DHM.
- Findings: Participants taking DHM showed improvements in blood markers related to liver stress (such as enzymes and inflammatory markers).
- Limitations: No liver biopsies were performed, so changes in liver tissue were not directly measured.
- Takeaway: Suggests potential benefit for liver enzyme balance, but replication is needed before conclusions can be drawn.
2. Hangover Mitigation – Hovenia dulcis and Flavonoid Blends
- Design: 2024 randomized, double-blind studies testing functional drinks containing Hovenia dulcis fruit extract, sometimes paired with flavonoids like Pueraria lobata and glutathione yeast.
- Findings: Participants reported fewer hangover-related symptoms and had lower blood alcohol and acetaldehyde levels compared to placebo.
- Important Note: These effects cannot be attributed to DHM alone; rather, they likely reflect the combined action of multiple botanicals.
- Takeaway: Combination formulas may offer additive or synergistic effects mirroring how most dietary supplements are formulated in practice.
3. First-in-Human Pharmacokinetic & Safety Trial (Phase I)
- Status: Phase I clinical trial registered to study purified DHM’s safety, absorption, and maximum tolerated dose in healthy adults.
- Timeline: Trial not yet recruiting as of 2025.
- Takeaway: This study will provide critical information about how DHM behaves in the human body.
4. Safety Overview
- Findings: DHM appears generally well tolerated in short-term human use. No reports of severe liver injury (e.g., jaundice) have been linked to DHM in published studies.
- Limitations: Only a few prospective safety trials exist, so we cannot assume safety across all doses or long-term use.
- Takeaway: Short-term data are reassuring, but large-scale studies are needed before broad health claims can be made.
5. Bioavailability Challenges
- Finding: Oral DHM has low absorption, which limits its overall bioavailability.
- Current Research: Scientists are testing nanoparticle, liposomal, and self-emulsifying delivery systems to enhance uptake.
- Takeaway: Improved delivery technologies could make DHM-based products more effective in the future, but human validation is still pending.
Key Takeaways
- Human data for DHM are limited but promising strongest support from a NAFLD trial showing improved liver markers.
- Most hangover-related benefits in humans have been seen with Hovenia dulcis extracts combined with other flavonoids, not DHM alone.
- Combination formulas may offer synergistic benefits, aligning with how functional recovery supplements are built.
- A Phase I safety and pharmacokinetic trial will clarify absorption and dosing.
- Short-term safety looks strong, but long-term data are lacking.
- Bioavailability remains DHM’s main technical challenge; new delivery systems are under study.
Bottom Line
DHM remains one of the most promising natural compounds for supporting liver and recovery pathways but the science is still evolving.
The early evidence is exciting, yet responsible communication (and continued research) are key to realizing its full potential.